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Korean Type 2 Diabetes Patients have Multiple Adenomatous 
Polyps Compared to Non-diabetic Controls
We tested the correlation between diabetes and aggressiveness of colorectal polyps in 
diabetic patients and matched non-diabetic controls. We retrospectively studied 3,505 
type 2 diabetes (T2DM) patients without gastrointestinal symptoms who underwent 
colonoscopy for colorectal cancer at Samsung Medical Center, Seoul, Korea from August 
1995 to August 2009. We matched 495 non-diabetic subjects with colon polyps to the 
diabetic patients in whom polyps were detected by year of colonoscopy, age, sex and body 
mass index (BMI). Among the 3,505 T2DM patients screened, 509 were found to have 
1,136 colon polyps. Those with diabetes had a greater proportion of adenomatous polyps 
(62.8% vs 53.6%) compared to the control. Multivariate logistic regression analysis 
identified DM, male gender, age and BMI as independent risk factors for multiple polyps 
(more than three polyps). Polyp multiplicity in diabetic patients was significantly associated 
with male gender (OR 2.360, P = 0.005), age (OR 1.033, P = 0.005) and BMI (OR 1.077, 
P = 0.028). Neither aspirin nor metformin use affected either size or number of polyps in 
diabetic patients. Male patients older than 65 yr with T2DM and BMI greater than 25 have 
increased risk for multiple adenomatous polyps and should be screened with colonoscopy 
to prevent colorectal cancer.
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INTRODUCTION
Diabetes mellitus (DM) is a serious and growing health problem 
worldwide and is associated with severe acute and chronic com-
plications. The industrialization and economic growth accom-
panied by the so-called ‘westernization’ of lifestyle, character-
ized by a high-calorie diet, obesity and physical inactivity may 
explain this diabetes epidemic. As a result of this change, the 
mortality of lifestyle-related diseases such as cancer, diabetes 
and cardiovascular disease has increased in many countries in-
cluding Korea. Worldwide, cancer is the second leading cause of 
death and diabetes is the 12th (1). According to Statistics Korea 
report of 2009 (2), cancer is the leading cause of death in Korea 
and DM is the 5th most common cause of death. In Korea, the 
incidence and mortality of colorectal cancer have risen steadily, 
and now positioned at the 4th most common type of cancer (2) 
following malignancies of the lung, liver and stomach. Epidemi-
ologic evidence suggests that people with diabetes are at signifi-
cantly higher risk for various cancers (3) because they share com-
mon risk factors such as age, obesity and physical inactivity. A 
recent meta-analysis associates diabetes with a relative risk of 
1.29-1.36 for cancers of colon and rectum (4). In addition to its 
role as an independent risk factor for tumor development, dia-
betes may influence cancer prognosis. Several studies show that 
diabetes increases risk for cancer mortality (5, 6).
  Screening of colorectal cancer is important because 80% of 
these cancers are believed to arise from adenomatous polyps 
that progress from severe dysplasia to invasive carcinoma (7). 
Therefore, discovery and removal of these precursor lesions can 
decrease the colorectal cancer incidence by 76% to 90% (8). 
  Although the link between diabetes and colorectal cancer is 
well established, few studies have addressed the association be-
tween diabetes and colon polyps. In this study, we tested the 
correlation between diabetes and aggressiveness of colorectal 
polyps in diabetic patients and matched them with non-diabet-
ic controls for the first time.
MATERIALS AND METHODS
Study population
We performed a retrospective study of consecutive type 2 dia-
betes (T2DM) patients without any gastrointestinal symptoms 
who underwent colonoscopic screening for colorectal cancer at 
the Diabetes Center, Samsung Medical Center in Seoul, Korea, 
from August 1995 to August 2009. We have chosen colonoscopy 
instead of fecal occult blood test and sigmoidoscopy for the fol-Suh S, et al.  •  T2DM Predicts Multiplicity in Colon Polyps
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lowing reason. Flexible sigmoidoscopy can only identify lesions 
in the distal 60 cm of the bowel and abnormal findings in the 
distal bowel require colonoscopy for visualization of the entire 
colon. On the other hand, colonoscopic examination showed 
the highest effectiveness for screening colon cancer (9) because 
the procedure can visualize the entire colon and lesions can be 
removed at the same time. The exclusion criteria included a his-
tory of colonic disease, such as colitis, polyps, or cancer; prior 
colonic surgery or colon polypectomy, and medical history of 
severe hematologic or connective disorders or other malignan-
cies. The criteria for type 2 diabetes mellitus (T2DM) included 
symptoms of DM (polyuria, polydipsia or unexplained weight 
loss) plus a random plasma glucose concentration of at least 200 
mg/dL; a fasting plasma glucose level of 126 mg/dL or higher; 
and a 2-hr plasma glucose level of 200 mg/dL or higher during 
an oral glucose tolerance test.
Data collection
Of the 3,505 T2DM patients screened (2,528 men and 977 wom-
en), 509 (417 men and 92 women) were found to have colon 
polyps. Following colonoscopy with polypectomy was done to 
these patients. Nine patients did not receive polypectomy be-
cause they were receiving continuous anti-coagulation medica-
tion (such as aspirin or warfarin) at the time of the procedure. 
The non-diabetic subjects with colon polyps were matched with 
the 509 diabetic patients with polyps for characteristics (year of 
colonoscopy, age, sex and body mass index) to clarify the impact 
of DM on colon polyp. The non-diabetic control subjects with 
polyps (i.e., without history of DM diagnosis or medication and 
HbA1c < 5.7%) were pooled from the database of the Center for 
Health Promotion, Samsung Medical Center. Excluding those 
with discordances in the year of the procedure, age and sex, 
34,628 persons were eligible for matching and from these, 495 
were selected by use of a statistical matching tool. We retrospec-
tively evaluated medical records of each patient for data on fast-
ing serum glucose, HbA1c, duration of diabetes, C-peptide, to-
tal cholesterol, triglyceride, low-density lipoprotein, high-den-
sity lipoprotein and history of aspirin and metformin use at the 
time of colonoscopy. The pathology database at Samsung Med-
ical Center was interrogated to provide information on all pa-
tients who had removed polyps between August 1995 and Au-
gust 2009. The aggressiveness of colorectal polyps was measured 
by polyp size, and number of polyps. Polyps with size greater 
than 10 mm or number more than three were defined as aggres-
sive polyp (10). Data on lifestyle habits such as smoking, alcohol 
consumption and physical activity were unavailable. 
Statistical analysis
Statistical analysis was performed using PASW Statistics 18.0 for 
Windows (SPSS Inc., IL, USA). All data were summarized as the 
mean ± standard deviation or number and percent. For all sta-
tistical analyses, a two-sided P value of < 0.05 was considered 
significant. The chi-square test was used to compare the differ-
ences in variables between the two groups. The Mann-Whitney 
test and Spearman’s correlation analysis were used to test cor-
relations of variables with size and number of colon polyps. All 
variables that resulted in P value < 0.05 in univariate analysis 
were entered into a logistic regression analysis to assess the in-
dependent association between risk factors and the size and 
number of polyps.
Ethics statement
The institutional review board of the Samsung Medical Center, 
Seoul, Korea approved this study protocol (2010-11-069-001). 
Informed consent was exempted by the board due to the retro-
spective design.
RESULTS
Diabetic patients with or without polyps
Among 3,505 patients with T2DM who underwent colonoscopy, 
509 were found to have 1,136 colon polyps. Characteristics of 
diabetic patients with or without colon polyps are summarized 
in Table 1. Compared to the subjects without polyps, those with 
polyps were older and had lower fasting plasma glucose levels 
and were more likely to be male. 
Table 1. Clinical characteristics of diabetic patients with or without colon polyps
Parameters No polyp (n = 2996) Polyp (n = 509) P value
Sex (M/F) 2,111 (70.5%)/  
  885 (29.5%)
417 (81.9%)/  
 92 (18.1%) 
< 0.001
Age (yr) 53.86 ± 9.62 55.98 ± 9.06 < 0.001
DM duration (yr)   6.24 ± 4.44   6.40 ± 4.32 0.455
BMI (kg/m
2) 24.95 ± 2.90 25.01 ± 3.03 0.714
HbA1c (%)   7.08 ± 1.75   7.00 ± 1.39 0.226
Fasting plasma glucose 
   (mg/dL)
139.92 ± 52.21 135.44 ± 43.64 0.038
C-peptide (ng/mL)   2.41 ± 1.20   2.41 ± 1.17 0.957
DM, Diabetes mellitus; BMI, body mass index.







Sex (M/F) 417/92 407/88 0.935
Age (yr) 55.98 ± 9.06 55.83 ± 8.56 0.782
Polyp size (mm)   5.80 ± 4.43   4.54 ± 3.88 < 0.001
Polyp number   2.23 ± 1.81   1.54 ± 1.08 < 0.001
Large polyps   81 (15.9%) 41 (8.3%) < 0.001
Multiple polyps 144 (28.3%)   59 (11.9%) < 0.001
BMI (kg/m
2) 25.01 ± 3.03 24.70 ± 2.75 0.089
HbA1c (%)   7.00 ± 1.39   5.21 ± 0.30 < 0.001
Fasting plasma glucose 
   (mg/dL)
135.44 ± 43.64 92.15 ± 9.68 < 0.001
Data are shown as means ± SD or number (percent). T2DM, type 2 diabetes; Polyp 
size, Largest polyp per individual; Large polyp, polyps with size ≥ 10 mm; Multiple 
polyps, polyp number more than three; BMI, body mass index.Suh S, et al.  •  T2DM Predicts Multiplicity in Colon Polyps
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Diabetic and non-diabetic groups with colon polyps
Baseline characteristics of 495 matched non-diabetic control 
subjects with colon polyp are shown in Table 2. Polyp size indi-
cates size of the largest polyp found in an individual. Polyps in 
diabetic patients were larger and more numerous than the ones 
in non-diabetic subjects, even though the two groups did not dif-
fer significantly in gender, age and body mass index (BMI). More-
over, percentage of aggressive polyp was higher in diabetic pa-
tients (15.9 vs 8.3 and 28.3 vs11.9, respectively). All polyps were 
removed during endoscopy and examined histologically except 
in 10 subjects (9 with diabetes and one control) who were tak-
ing anti-platelet agents at the time of the procedure (Table 3). 
The proportion of adenomatous polyps was greater in diabetic 
than in non-diabetic subjects (62.8% vs 53.6%) but the propor-
tion of adenocarcinoma did not differ significantly between these 
groups. 
Risk factors for aggressive polyps
Multivariate logistic regression analysis identified DM, male gen-
der, age and BMI as independent risk factors for multiple (more 
than three) polyps (Table 4). No independent risk factor for pol-
yp size was identified among the patients with diabetes (data 
not shown). However, multiple polyps in the diabetic patients 
were significantly associated with male gender (OR 2.360, 95% 
CI 1.303-4.276, P = 0.005), age (OR 1.033, 95% CI 1.010-1.057, P 
= 0.005) and BMI (OR 1.077, 95% CI 1.008-1.151, P = 0.028). As a 
practical guide to evaluation, the OR was calculated by quartile 
for age and BMI (Table 5). Male diabetic patients with age ≥ 65 
and BMI ≥ 25 were at risk for having multiple polyps. No inde-
pendent risk factor for multiple polyps emerged from data for 
the non-diabetic controls (data not shown). Through a retro-
spective chart review we determined that 26.7% (136/509) and 
29.9% (152/509) of the diabetic patients were taking aspirin or 
metformin, respectively, at the time of colonoscopy. However, 
neither medication was correlated with the size or the number 
of polyps observed (data not shown). 
DISCUSSION
This study confirmed an association between diabetes and mul-
tiplicity of colon polyps for the first time. Diabetic patients also 
had more aggressive and adenomatous polyps than the non-di-
abetic controls, which may indicate higher risk of progression 
to colorectal cancer.
  A polyp of colon is a focal protuberance into the lumen from 
the normally flat colonic mucosa. The prevalence rate of polyps 
is known to be 20% to 40%. Among the 3,505 patients in our 
study, 509 (14.5%) were found to have colon polyps. This preva-
lence rate was not higher than the rate in the previous screen-
ing studies and was lower than other studies in Asian countries 
(11-13). This result may reflect the shortcoming of our study to 
a single-center population. Age and male gender are known to 
represent significant risk factors for polyps (14-17) and these 
associations are held true in our diabetic patients. Although di-
abetic patients with polyps had slightly lower fasting plasma glu-
cose (P = 0.038), their average HbA1c (about 7%) did not differ 
significantly from the level of those without polyps. The preva-
lence of polyps in DM patients did not differ significantly with 
respect to fasting plasma glucose (≥ 154 mg/dL vs < 154 mg/dL) 
or HbA1c (HbA1c ≥ 7% vs HbA1c < 7%) (data not shown).
  Diabetic patients had larger polyps with greater multiplicity, 
but the prevalence rate of adenocarcinoma was similar in both 
Table 3. Colorectal polyp histology in diabetic and non-diabetic subjects
Pathology   T2DM patients  
  (n = 509)
  Non-diabetic controls  
  (n = 495)
Total polyp number*   1,136   760
Tubular adenoma   701 (61.7%)    397 (52.2%)
Tubulovillous adenoma     7 (0.6%)      9 (1.2%)
Villous adenoma     5 (0.4%)      1 (0.1%)
Hyperplastic polyp   235 (20.7%) 228 (30%)
Inflammatory polyp   26 (2.3%)      8 (1.1%)
No pathologic alteration 112 (9.9%)    69 (9.1%)
Adenocarcinoma     6 (0.5%)      3 (0.4%)
Others
†   30 (2.6%)    44 (5.8%)
No polypectomy   14 (1.2%)      1 (0.1%)
Data are shown as number (percent). *Total number of polyps found in each group; 
†Pathologic findings other than previously described.
Table 4. Mutivariate logistic regression analysis of variables for multiple (more than 
three) polyps
Variables OR 95% CI P value
Male 3.580 2.034-6.300 < 0.001
Diabetes 2.847 1.828-4.436 < 0.001
Age 1.033 1.013-1.053 0.001
BMI 1.066 1.008-1.128 0.026
TC 0.999 0.994-1.004 0.576
HDL 1.000 0.986-1.015 0.976
TG 1.001 0.999-1.003 0.281
Fasting plasma glucose 0.998 0.992-1.004 0.439
HbA1c 1.049 0.869-1.266 0.618
BMI, body mass index; TC, total cholesterol; HDL, high-density lipoprotein; TG, triglyc-
eride.
Table 5. Analysis of risk factors for multiple polyps in diabetic patients
Variables OR 95% CI P value
Sex
   Female
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   20≤ BMI <25
   25≤ BMI <30
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groups. Increasing polyp size, a higher number of polyps, villous 
histology and high-grade dysplasia are risk factors for focal can-
cer within an individual adenoma (18). Number and size are the 
most consistent risk factors for metachronous adenomas includ-
ing advanced adenomas and cancer. In general, polyps with size 
more than 10 mm or number more than three are known as high 
risk for colorectal cancer (9). The proportion of these aggressive 
polyps was higher in T2DM patients (Table 2). Moreover, ade-
nomatous polyp, a premalignant lesion that tends to progress 
into colorectal cancer via the traditional adenoma-carcinoma 
sequence, was more common in the diabetic group than in the 
non-diabetic control group (Table 3). A multivariate logistic re-
gression analysis of our data identified diabetes, male gender, 
age and BMI as independent risk factors for multiple (more nu-
merous than three) polyps. Interestingly, serum fasting glucose 
and lipid levels were not associated with polyp size or number. 
The influence of these factors was probably minor, if any and may 
have been obscured by the significantly larger (2.85-fold) impact 
of diabetes on polyps in the multivariable analysis (Table 4).
  In testing variables as independent risk factors for polyp ag-
gressiveness in diabetic subjects, we found that none was asso-
ciated with polyp size. However, multiple polyps were signifi-
cantly associated with male gender (OR 2.360, 95% CI 1.303-
4.276, P = 0.005), age (OR 1.033, 95% CI 1.010-1.057, P = 0.005) 
and BMI (OR 1.077, 95% CI 1.008-1.151, P = 0.028). For clinical 
guidance, we analyzed OR for age and BMI by quartile, and found 
that diabetic patients with age ≥ 65, BMI ≥ 25 and male gender 
were more likely to have multiple polyps (Table 5). From these 
results, we can speculate that diabetes have influence on the 
number of polyps although not on the size reflecting its effect 
on polyps’ formation not their development. Chronic hyperin-
sulinemia may favor cancer initiation and progression in diabet-
ic patients due to the mitogenic effect of insulin (19). Prospective 
epidemiologic studies of biomarkers of insulin resistance show 
that individuals with higher insulin levels are at higher risk for 
colon cancer (20). Rather than measuring serum insulin levels, 
we measured C-peptide, because some of the patients enrolled 
in this study were using insulin to control diabetes. However, C-
peptide levels were not correlated with polyp-related variables 
(i.e. size and number) in our study, which may stem from the 
small number of patients in our study as compared to the larger 
ones. A 10-yr prospective cohort study of 1.3 million Koreans 
aged 30 to 95 yr showed that serum glucose concentration was 
strongly associated with colon cancer (5). However, we did not 
find a relationship between HbA1c or serum glucose level and 
characteristics of colon polyps. This finding may be explained 
by rather good control of plasma glucose (HbA1c around 7%) 
in our study. Kim et al. (21) also reported that increased serum 
fasting glucose was not associated with the development of co-
lon adenoma in metabolic syndrome subjects. Moreover, sub-
group analysis in our study failed to correlate fasting plasma glu-
cose and HbA1c levels with colon polyp multiplicity or size. The 
absence of association between metabolic risk factors and pol-
yps may be due to a narrower range of values of metabolic vari-
ables, which could have been influenced by patient medication. 
This implies that diabetes itself, although in good control, is as-
sociated with multiplicity of colon polyps. Diabetes is a complex 
metabolic disorder and hyperglycemia alone may not explain 
all of its deleterious effects on polyps. Usually by the time a di-
agnosis of diabetes is made, endogenous hyperinsulinemia has 
been maintained for a significant period time, even as pancre-
atic beta-cell function starts to decline. Eventually, decreased 
beta-cell function becomes unable to overcome insulin resis-
tance and exogenous insulin therapy is required. Thus, T2DM 
patients may have longer exposure to hyperinsulinemia than to 
hyperglycemia. However, these hypothetical mechanisms await 
further study.
  Numerous studies confirm an inverse association between 
aspirin use and risk of colorectal cancer (22). A mounting body 
of evidence suggests that metformin may also reduce cancer risk 
in diabetic patients (23). In this study, however, neither regular 
aspirin nor metformin use showed any effect on clinical behav-
ior of the polyps. Siddiqui et al. (24) also failed to find the asso-
ciation between aspirin use and polyp characteristics in T2DM 
patients. The preventive role of aspirin to colorectal cancer is 
strongly associated with higher dosage (≥ 500 mg daily) and lon-
ger duration (≥ 10 yr) of use (25). Low-dose aspirin use to reduce 
cardiovascular risks in diabetic patients may fall short of a pro-
tective role in cancer. Metformin use to protect against colorec-
tal polyp should be tested further in a large long-term prospec-
tive study. 
  We attempted to balance the limitations in this study with cor-
responding advantages. Although subjects in this study were 
selected from a single-center population, we matched diabetic 
and non-diabetic subjects by contrast to clarify by contrast the 
effects of diabetes on colon polyps. Data on lifestyle habits such 
as smoking, alcohol consumption and physical activity were ex-
cluded by the retrospective design. On the other hand, this study 
had the methodological advantage that colonoscopy was done 
for all subjects found to have polyps leaving no hidden ones. To 
our knowledge, this is the first study to compare characteristics 
of colon polyps in matched diabetic and non-diabetic subjects.
  In conclusion, male T2DM patients older than 65 yr and BMI 
more than 25 have increased risk for multiple adenomatous pol-
yps. These individuals should be encouraged to undergo screen-
ing with colonoscopy to prevent colorectal cancer.
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